Aging, atherosclerosis, and IGF-1

Journals of Gerontology - Series A Biological Sciences and Medical Sciences

Volumn 67 A, Issue 6, 2012, Pages 626-639

  Higashi, Yusuke ^a   Sukhanov, Sergiy ^a   Anwar, Asif ^a   Shai, Shaw Yung ^a   Delafontaine, Patrice ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aging; Atherosclerosis; IGF 1; Inflammation; Oxidant stress

Indexed keywords

ANIMALIA;

SOMATOMEDIN C;

AGING; ANIMAL; APOPTOSIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; DISEASE MODEL; DRUG EFFECT; FEMALE; HUMAN; INFLAMMATION; LONGEVITY; MALE; METABOLISM; MOUSE; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHYSIOLOGY; RAT; REVIEW;

AGING; ANIMALS; APOPTOSIS; ATHEROSCLEROSIS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; INFLAMMATION; INSULIN-LIKE GROWTH FACTOR I; LONGEVITY; MALE; MICE; OXIDATIVE STRESS; PLAQUE, ATHEROSCLEROTIC; RATS;

EID: 84861039037     PISSN: 10795006     EISSN: 1758535X     Source Type: Journal    
DOI: 10.1093/gerona/gls102     Document Type: Review

References (199)

1. Witztum JL. The oxidation hypothesis of atherosclerosis. Lancet. 1994;344:793-795. (Pubitemid 24283962)
2. Finkel T, Holbrook NJ. Oxidants, oxidative stress and the biology of ageing. Nature. 2000;408:239-247.
3. Cercek B, Fishbein MC, Forrester JS, Helfant RH, Fagin JA. Induction of insulin-like growth factor I messenger RNA in rat aorta after balloon denudation. Circ Res. 1990;66:1755-1760.
4. Hayry P, Myllarniemi M, Aavik E, et al. Stabile D-peptide analog of insulin-like growth factor-1 inhibits smooth muscle cell proliferation after carotid ballooning injury in the rat. FASEB J. 1995;9:1336-1344.
5. Maile LA, Capps BE, Ling Y, Xi G, Clemmons DR. Hyperglycemia alters the responsiveness of smooth muscle cells to insulin-like growth factor-I. Endocrinology. 2007;148:2435-2443. (Pubitemid 46997046)
6. Sukhanov S, Higashi Y, Shai SY, Vaughn C, Mohler J, Li Y, et al. IGF-1 reduces inflammatory responses, suppresses oxidative stress, and decreases atherosclerosis progression in ApoE-deficient mice. Arterioscler Thromb Vasc Biol. 2007;27:2684-2690. (Pubitemid 350158923)
7. Frutkin AD, Otsuka G, Stempien-Otero A, et al. TGF-[beta]1 limits plaque growth, stabilizes plaque structure, and prevents aortic dilation in apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol. 2009;29:1251-1257.
8. Tang J, Kozaki K, Farr AG, et al. The absence of platelet-derived growth factor-B in circulating cells promotes immune and inflammatory responses in atherosclerosis-prone ApoE-/-mice. Am J Pathol. 2005;167:901-912. (Pubitemid 41216372)
9. Kozaki K, Kaminski WE, Tang J, et al. Blockade of platelet-derived growth factor or its receptors transiently delays but does not prevent fibrous cap formation in ApoE null mice. Am J Pathol. 2002;161:1395-1407.
10. Raines EW, Ferri N. Thematic review series: the immune system and atherogenesis. Cytokines affecting endothelial and smooth muscle cells in vascular disease. J Lipid Res. 2005;46:1081-1092. (Pubitemid 43109823)
11. LeRoith D, Werner H, Beitner-Johnson D, Roberts CT Jr. Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev. 1995;16:143-163.
12. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev. 1995;16:3-34.
13. Delafontaine P. Insulin-like growth factor I and its binding proteins in the cardiovascular system. Cardiovasc Res. 1995;30:825-834.
14. Le Roith D. Seminars in medicine of the Beth Israel Deaconess Medical Center. Insulin-like growth factors. N Engl J Med. 1997;336:633-640.
15. Tsuruzoe K, Emkey R, Kriauciunas KM, Ueki K, Kahn CR. Insulin receptor substrate 3 (IRS-3) and IRS-4 impair IRS-1-and IRS-2-mediated signaling. Mol Cell Biol. 2001;21:26-38.
16. Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature. 2001;414:799-806. (Pubitemid 34000783)
17. Stewart CE, Rotwein P. Growth, differentiation, and survival: multiple physiological functions for insulin-like growth factors. Physiol Rev. 1996;76:1005-1026. (Pubitemid 26346814)
18. Bailyes EM, Nave BT, Soos MA, Orr SR, Hayward AC, Siddle K. Insulin receptor/IGF-I receptor hybrids are widely distributed in mammalian tissues: quantification of individual receptor species by selective immunoprecipitation and immunoblotting. Biochem J. 1997;327(Pt 1):209-215. (Pubitemid 27455481)
19. Chisalita SI, Arnqvist HJ. Expression and function of receptors for insulin-like growth factor-I and insulin in human coronary artery smooth muscle cells. Diabetologia. 2005;48:2155-2161. (Pubitemid 41416929)
20. Higashi Y, Holder K, Delafontaine P. Thiazolidinediones up-regulate insulin-like growth factor-1 receptor via a peroxisome proliferator-activated receptor gamma-independent pathway. J Biol Chem. 2010;285:36361-36368.
21. Engberding N, San Martin A, Martin-Garrido A, et al. Insulin-like growth factor-1 receptor expression masks the antiinflammatory and glucose uptake capacity of insulin in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2009;29:408-415.
22. Chisalita SI, Arnqvist HJ. Insulin-like growth factor I receptors are more abundant than insulin receptors in human micro-and macrovascular endothelial cells. Am J Physiol Endocrinol Metab. 2004;286:E896-E901. (Pubitemid 38668810)
23. Li G, Barrett EJ, Wang H, Chai W, Liu Z. Insulin at physiological concentrations selectively activates insulin but not insulin-like growth factor I (IGF-I) or insulin/IGF-I hybrid receptors in endothelial cells. Endocrinology. 2005;146:4690-4696. (Pubitemid 41446606)
24. Schneider MR, Lahm H, Wu M, Hoeflich A, Wolf E. Transgenic mouse models for studying the functions of insulin-like growth factor-binding proteins. FASEB J. 2000;14:629-640. (Pubitemid 30198562)
25. Sakai K, Busby WH Jr., Clarke JB, Clemmons DR. Tissue transglutaminase facilitates the polymerization of insulin-like growth factor-binding protein-1 (IGFBP-1) and leads to loss of IGFBP-1's ability to inhibit insulin-like growth factor-I-stimulated protein synthesis. J Biol Chem. 2001;276:8740-8745.
26. Jones JI, Gockerman A, Busby WH Jr., Wright G, Clemmons DR. Insulin-like growth factor binding protein 1 stimulates cell migration and binds to the alpha 5 beta 1 integrin by means of its Arg-Gly-Asp sequence. Proc Natl Acad Sci USA. 1993;90:10553-10557. (Pubitemid 23347080)
27. Sisci D, Surmacz E. Crosstalk between IGF signaling and steroid hormone receptors in breast cancer. Curr Pharm Des. 2007;13:705-717. (Pubitemid 46510746)
28. Tao Y, Pinzi V, Bourhis J, Deutsch E. Mechanisms of disease: signaling of the insulin-like growth factor 1 receptor pathway-therapeutic perspectives in cancer. Nat Clin Pract Oncol. 2007;4:591-602. (Pubitemid 47534758)
29. Bayes-Genis A, Conover CA, Schwartz RS. The insulin-like growth factor axis: a review of atherosclerosis and restenosis. Circ Res. 2000;86:125-130. (Pubitemid 30086171)
30. Conti E, Carrozza C, Capoluongo E, et al. Insulin-like growth factor-1 as a vascular protective factor. Circulation. 2004;110:2260-2265. (Pubitemid 39372511)
31. Delafontaine P, Song YH, Li Y. Expression, regulation, and function of IGF-1, IGF-1R, and IGF-1 binding proteins in blood vessels. Arterioscler Thromb Vasc Biol. 2004;24:435-444. (Pubitemid 38326135)
32. Arnqvist HJ. The role of IGF-system in vascular insulin resistance. Horm Metab Res. 2008;40:588-592.
33. Renier G, Clement I, Desfaits AC, Lambert A. Direct stimulatory effect of insulin-like growth factor-I on monocyte and macrophage tumor necrosis factor-alpha production. Endocrinology. 1996;137:4611-4618. (Pubitemid 26403296)
34. Che W, Lerner-Marmarosh N, Huang Q, et al. Insulin-like growth factor-1 enhances inflammatory responses in endothelial cells: role of Gab1 and MEKK3 in TNF-alpha-induced c-Jun and NF-kappaB activation and adhesion molecule expression. Circ Res. 2002;90:1222-1230. (Pubitemid 34786908)
35. Li G, Barrett EJ, Ko SH, Cao W, Liu Z. Insulin and insulin-like growth factor-I receptors differentially mediate insulin-stimulated adhesion molecule production by endothelial cells. Endocrinology. 2009;150:3475-3482.
36. Libby P, Sasiela W. Plaque stabilization: Can we turn theory into evidence? Am J Cardiol. 2006;98:26P-33P.
37. Andreassen M, Raymond I, Kistorp C, Hildebrandt P, Faber J, Kristensen LO. IGF1 as predictor of all cause mortality and cardiovascular disease in an elderly population. Eur J Endocrinol. 2009;160:25-31.
38. Boquist S, Ruotolo G, Skoglund-Andersson C, et al. Correlation of serum IGF-I and IGFBP-1 and-3 to cardiovascular risk indicators and early carotid atherosclerosis in healthy middle-aged men. Clin Endocrinol (Oxf). 2008;68:51-58. (Pubitemid 350243481)
39. Botker HE, Skjaerbaek C, Eriksen UH, Schmitz O, Orskov H. Insulin-like growth factor-I, insulin, and angina pectoris secondary to coronary atherosclerosis, vasospasm, and syndrome X. Am J Cardiol. 1997;79:961-963. (Pubitemid 27197933)
40. Fischer F, Schulte H, Mohan S, et al. Associations of insulin-like growth factors, insulin-like growth factor binding proteins and acid-labile subunit with coronary heart disease. Clin Endocrinol (Oxf). 2004;61:595-602. (Pubitemid 39540361)
41. Kawachi S, Takeda N, Sasaki A, et al. Circulating insulin-like growth factor-1 and insulin-like growth factor binding protein-3 are associated with early carotid atherosclerosis. Arterioscler Thromb Vasc Biol. 2005;25:617-621. (Pubitemid 40315687)
42. Ruotolo G, Bavenholm P, Brismar K, et al. Serum insulin-like growth factor-I level is independently associated with coronary artery disease progression in young male survivors of myocardial infarction: beneficial effects of bezafibrate treatment. J Am Coll Cardiol. 2000;35:647-654. (Pubitemid 30167021)
43. Schuler-Luttmann S, Monnig G, Enbergs A, et al. Insulin-like growth factor-binding protein-3 is associated with the presence and extent of coronary arteriosclerosis. Arterioscler Thromb Vasc Biol. 2000;20:E10-E15.
44. Conti E, Andreotti F, Sestito A, et al. Reduced levels of insulin-like growth factor-1 in patients with angina pectoris, positive exercise stress test, and angiographically normal epicardial coronary arteries. Am J Cardiol. 2002;89:973-975. (Pubitemid 34310298)
45. Friedrich N, Haring R, Nauck M, et al. Mortality and serum insulin-like growth factor (IGF)-I and IGF binding protein 3 concentrations. J Clin Endocrinol Metab. 2009;94:1732-1739.
46. Goodman-Gruen D, Barrett-Connor E, Rosen C. IGF-1 and ischemic heart disease in older people. J Am Geriatr Soc. 2000;48:860-861. (Pubitemid 30457437)
47. Janssen JA, Stolk RP, Pols HA, Grobbee DE, de Jong FH, Lamberts SW. Serum free IGF-I, total IGF-I, IGFBP-1 and IGFBP-3 levels in an elderly population: relation to age and sex steroid levels. Clin Endocrinol (Oxf). 1998;48:471-478. (Pubitemid 28258820)
48. Juul A, Scheike T, Davidsen M, Gyllenborg J, Jorgensen T. Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study. Circulation. 2002;106:939-944. (Pubitemid 34925327)
49. Laughlin GA, Barrett-Connor E, Criqui MH, Kritz-Silverstein D. The prospective association of serum insulin-like growth factor I (IGF-I) and IGF-binding protein-1 levels with all cause and cardiovascular disease mortality in older adults: the Rancho Bernardo Study. J Clin Endocrinol Metab. 2004;89:114-120. (Pubitemid 38183869)
50. Martin RM, Gunnell D, Whitley E, et al. Associations of insulin-like growth factor (IGF)-I, IGF-II, IGF binding protein (IGFBP)-2 and IGFBP-3 with ultrasound measures of atherosclerosis and plaque stability in an older adult population. J Clin Endocrinol Metab. 2008;93:1331-1338. (Pubitemid 351519729)
51. Roubenoff R, Parise H, Payette HA, et al. Cytokines, insulin-like growth factor 1, sarcopenia, and mortality in very old community-dwelling men and women: the Framingham Heart Study. Am J Med. 2003;115:429-435. (Pubitemid 37237554)
52. Spallarossa P, Brunelli C, Minuto F, et al. Insulin-like growth factor-I and angiographically documented coronary artery disease. Am J Cardiol. 1996;77:200-202.
53. van den Beld AW, Bots ML, Janssen JA, Pols HA, Lamberts SW, Grobbee DE. Endogenous hormones and carotid atherosclerosis in elderly men. Am J Epidemiol. 2003;157:25-31. (Pubitemid 36043733)
54. Ruidavets JB, Luc G, Machez E, et al. Effects of insulin-like growth factor 1 in preventing acute coronary syndromes: the PRIME study. Atherosclerosis. 2011;218:464-469.
55. Harrela M, Qiao Q, Koistinen R, et al. High serum insulin-like growth factor binding protein-1 is associated with increased cardiovascular mortality in elderly men. Horm Metab Res. 2002;34:144-149. (Pubitemid 34293272)
56. Kaplan RC, McGinn AP, Pollak MN, et al. Association of total insulin-like growth factor-I, insulin-like growth factor binding protein-1 (IGFBP-1), and IGFBP-3 levels with incident coronary events and ischemic stroke. J Clin Endocrinol Metab. 2007;92:1319-1325. (Pubitemid 46556404)
57. Lawlor DA, Ebrahim S, Smith GD, Cherry L, Watt P, Sattar N. The association of insulin-like-growth factor 1 (IGF-1) with incident coronary heart disease in women: findings from the prospective British Women's Heart and Health Study. Atherosclerosis. 2008;201:198-204.
58. Maggio M, Lauretani F, Ceda GP, et al. Relationship between low levels of anabolic hormones and 6-year mortality in older men: the aging in the Chianti Area (InCHIANTI) study. Arch Intern Med. 2007;167:2249-2254. (Pubitemid 350106746)
59. Saydah S, Graubard B, Ballard-Barbash R, Berrigan D. Insulin-like growth factors and subsequent risk of mortality in the United States. Am J Epidemiol. 2007;166:518-526. (Pubitemid 47283642)
60. Wallander M, Norhammar A, Malmberg K, Ohrvik J, Ryden L, Brismar K. IGF binding protein 1 predicts cardiovascular morbidity and mortality in patients with acute myocardial infarction and type 2 diabetes. Diabetes Care. 2007;30:2343-2348. (Pubitemid 47359045)
61. Brugts MP, van den Beld AW, Hofland LJ, et al. Low circulating insulin-like growth factor I bioactivity in elderly men is associated with increased mortality. J Clin Endocrinol Metab. 2008;93:2515-2522. (Pubitemid 352008515)
62. Janssen JA, Stolk RP, Pols HA, Grobbee DE, Lamberts SW. Serum total IGF-I, free IGF-I, and IGFB-1 levels in an elderly population: relation to cardiovascular risk factors and disease. Arterioscler Thromb Vasc Biol. 1998;18:277-282. (Pubitemid 28277606)
63. Vaessen N, Heutink P, Janssen JA, et al. A polymorphism in the gene for IGF-I: functional properties and risk for type 2 diabetes and myocardial infarction. Diabetes. 2001;50:637-642. (Pubitemid 32195230)
64. Bleumink GS, Schut AF, Sturkenboom MC, et al. A promoter polymorphism of the insulin-like growth factor-I gene is associated with left ventricular hypertrophy. Heart. 2005;91:239-240.
65. Schut AF, Janssen JA, Deinum J, et al. Polymorphism in the promoter region of the insulin-like growth factor I gene is related to carotid intima-media thickness and aortic pulse wave velocity in subjects with hypertension. Stroke. 2003;34:1623-1627. (Pubitemid 36842614)
66. Yazdanpanah M, Rietveld I, Janssen JA, et al. An insulin-like growth factor-I promoter polymorphism is associated with increased mortality in subjects with myocardial infarction in an elderly Caucasian population. Am J Cardiol. 2006;97:1274-1276.
67. Yazdanpanah M, Sayed-Tabatabaei FA, Janssen JA, et al. IGF-I gene promoter polymorphism is a predictor of survival after myocardial infarction in patients with type 2 diabetes. Eur J Endocrinol. 2006;155:751-756. (Pubitemid 44857500)
68. Allen NE, Davey GK, Key TJ, Zhang S, Narod SA. Serum insulin-like growth factor I (IGF-I) concentration in men is not associated with the cytosine-adenosine repeat polymorphism of the IGF-I gene. Cancer Epidemiol Biomarkers Prev. 2002;11:319-320. (Pubitemid 34327013)
69. Frayling TM, Hattersley AT, McCarthy A, et al. A putative functional polymorphism in the IGF-I gene: association studies with type 2 diabetes, adult height, glucose tolerance, and fetal growth in U.K. populations. Diabetes. 2002;51:2313-2316. (Pubitemid 34729041)
70. Migliaccio E, Giorgio M, Mele S, et al. The p66shc adaptor protein controls oxidative stress response and life span in mammals. Nature. 1999;402:309-313. (Pubitemid 129516269)
71. Selman C, Lingard S, Choudhury AI, et al. Evidence for lifespan extension and delayed age-related biomarkers in insulin receptor substrate 1 null mice. FASEB J. 2008;22:807-818. (Pubitemid 351348133)
72. Suh Y, Atzmon G, Cho MO, et al. Functionally significant insulin-like growth factor I receptor mutations in centenarians. Proc Natl Acad Sci USA. 2008;105:3438-3442. (Pubitemid 351723571)
73. Fontana L, Partridge L, Longo VD. Extending healthy life span-from yeast to humans. Science. 2010;328:321-326.
74. Holzenberger M, Dupont J, Ducos B, et al. IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice. Nature. 2003;421:182-187. (Pubitemid 36090987)
75. Guevara-Aguirre J, Balasubramanian P, Guevara-Aguirre M, et al. Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans. Sci Transl Med. 2011;3:70ra13.
76. Bartke A, Wright JC, Mattison JA, Ingram DK, Miller RA, Roth GS. Extending the lifespan of long-lived mice. Nature. 2001;414:412. (Pubitemid 34173717)
77. Tsuchiya T, Dhahbi JM, Cui X, Mote PL, Bartke A, Spindler SR. Additive regulation of hepatic gene expression by dwarfism and caloric restriction. Physiol Genomics. 2004;17:307-315. (Pubitemid 38924176)
78. Colman RJ, Anderson RM, Johnson SC, et al. Caloric restriction delays disease onset and mortality in rhesus monkeys. Science. 2009;325:201-204.
79. Li H, Dimayuga P, Yamashita M, et al. Arterial injury in mice with severe insulin-like growth factor-1 (IGF-1) deficiency. J Cardiovasc Pharmacol Ther. 2002;7:227-233. (Pubitemid 35471358)
80. Zhu B, Zhao G, Witte DP, Hui DY, Fagin JA. Targeted overexpression of IGF-I in smooth muscle cells of transgenic mice enhances neointimal formation through increased proliferation and cell migration after intraarterial injury. Endocrinology. 2001;142:3598-3606. (Pubitemid 32681770)
81. Harrington SC, Simari RD, Conover CA. Genetic deletion of pregnancy-associated plasma protein-A is associated with resistance to atherosclerotic lesion development in apolipoprotein E-deficient mice challenged with a high-fat diet. Circ Res. 2007;100:1696-1702. (Pubitemid 46987861)
82. Nichols TC, Busby WH Jr, Merricks E, et al. Protease-resistant insulin-like growth factor (IGF)-binding protein-4 inhibits IGF-I actions and neointimal expansion in a porcine model of neointimal hyperplasia. Endocrinology. 2007;148:5002-5010. (Pubitemid 47481520)
83. Razuvaev A, Henderson B, Girnita L, et al. The cyclolignan picropodophyllin attenuates intimal hyperplasia after rat carotid balloon injury by blocking insulin-like growth factor-1 receptor signaling. J Vasc Surg. 2007;46:108-115. (Pubitemid 46990746)
84. Resch ZT, Simari RD, Conover CA. Targeted disruption of the pregnancy-associated plasma protein-A gene is associated with diminished smooth muscle cell response to insulin-like growth factor-I and resistance to neointimal hyperplasia after vascular injury. Endocrinology. 2006;147:5634-5640. (Pubitemid 44833480)
85. Niu XL, Li J, Hakim ZS, Rojas M, Runge MS, Madamanchi NR. Leukocyte antigen-related deficiency enhances insulin-like growth factor-1 signaling in vascular smooth muscle cells and promotes neointima formation in response to vascular injury. J Biol Chem. 2007;282:19808-19819. (Pubitemid 47100122)
86. Zadelaar S, Kleemann R, Verschuren L, et al. Mouse models for atherosclerosis and pharmaceutical modifiers. Arterioscler Thromb Vasc Biol. 2007;27:1706-1721. (Pubitemid 47207165)
87. Getz GS, Reardon CA. Diet and murine atherosclerosis. Arterioscler Thromb Vasc Biol. 2006;26:242-249. (Pubitemid 43732181)
88. Meir KS, Leitersdorf E. Atherosclerosis in the apolipoprotein-E-deficient mouse: a decade of progress. Arterioscler Thromb Vasc Biol. 2004;24:1006-1014. (Pubitemid 38737824)
89. Moghadasian MH, McManus BM, Nguyen LB, et al. Pathophysiology of apolipoprotein E deficiency in mice: relevance to apo E-related disorders in humans. FASEB J. 2001;15:2623-2630. (Pubitemid 33131089)
90. Adamo ML, Ma X, Ackert-Bicknell CL, Donahue LR, Beamer WG, Rosen CJ. Genetic increase in serum insulin-like growth factor-I (IGF-I) in C3H/HeJ compared with C57BL/6J mice is associated with increased transcription from the IGF-I exon 2 promoter. Endocrinology. 2006;147:2944-2955. (Pubitemid 43764630)
91. Nichols TC, du Laney T, Zheng B, et al. Reduction in atherosclerotic lesion size in pigs by alphaVbeta3 inhibitors is associated with inhibition of insulin-like growth factor-I-mediated signaling. Circ Res. 1999;85:1040-1045.
92. Ye P, D'Ercole J. Insulin-like growth factor I (IGF-I) regulates IGF binding protein-5 gene expression in the brain. Endocrinology. 1998;139:65-71. (Pubitemid 28166292)
93. Frystyk J. Free insulin-like growth factors-measurements and relationships to growth hormone secretion and glucose homeostasis. Growth Horm IGF Res. 2004;14:337-375. (Pubitemid 39185988)
94. Sukhanov S, Higashi Y, Shai SY, et al. Differential requirement for nitric oxide in IGF-1-induced anti-apoptotic, anti-oxidant and anti-atherosclerotic effects. FEBS Lett. 2011;585:3065-3072.
95. Titterington JS, Sukhanov S, Higashi Y, Vaughn C, Bowers C, Delafontaine P. Growth hormone-releasing peptide-2 suppresses vascular oxidative stress in ApoE-/-mice but does not reduce atherosclerosis. Endocrinology. 2009;150:5478-5487.
96. Andersson IJ, Ljungberg A, Svensson L, Gan LM, Oscarsson J, Bergstrom G. Increased atherosclerotic lesion area in apoE deficient mice overexpressing bovine growth hormone. Atherosclerosis. 2006;188:331-340. (Pubitemid 44301142)
97. Marin J. Age-related changes in vascular responses: a review. Mech Ageing Dev. 1995;79:71-114.
98. Payne JA, Reckelhoff JF, Khalil RA. Role of oxidative stress in age-related reduction of NO-cGMP-mediated vascular relaxation in SHR. Am J Physiol Regul Integr Comp Physiol. 2003;285:R542-R551. (Pubitemid 37040562)
99. Chung HY, Sung B, Jung KJ, Zou Y, Yu BP. The molecular inflammatory process in aging. Antioxid Redox Signal. 2006;8:572-581. (Pubitemid 43741326)
100. Shai SY, Sukhanov S, Higashi Y, Vaughn C, Rosen CJ, Delafontaine P. Low circulating insulin-like growth factor I increases atherosclerosis in ApoE-deficient mice. Am J Physiol Heart Circ Physiol. 2011;300:H1898-H1906.
101. Hammerman MR. Insulin-like growth factors and aging. Endocrinol Metab Clin North Am. 1987;16:995-1011. (Pubitemid 18090583)
102. D'Costa AP, Ingram RL, Lenham JE, Sonntag WE. The regulation and mechanisms of action of growth hormone and insulin-like growth factor 1 during normal ageing. J Reprod Fertil Suppl. 1993;46:87-98.
103. Breese CR, Ingram RL, Sonntag WE. Influence of age and long-term dietary restriction on plasma insulin-like growth factor-1 (IGF-1), IGF-1 gene expression, and IGF-1 binding proteins. J Gerontol. 1991;46:B180-B187.
104. Khan AS, Sane DC, Wannenburg T, Sonntag WE. Growth hormone, insulin-like growth factor-1 and the aging cardiovascular system. Cardiovasc Res. 2002;54:25-35.
105. Shai SY, Sukhanov S, Higashi Y, Vaughn C, Kelly J, Delafontaine P. Smooth muscle cell-specific insulin-like growth factor-1 overexpression in Apoe-/-mice does not alter atherosclerotic plaque burden but increases features of plaque stability. Arterioscler Thromb Vasc Biol. 2010;30:1916-1924.
106. Dardevet D, Sornet C, Attaix D, Baracos VE, Grizard J. Insulin-like growth factor-1 and insulin resistance in skeletal muscles of adult and old rats. Endocrinology. 1994;134:1475-1484. (Pubitemid 24085607)
107. Willis PE, Chadan SG, Baracos V, Parkhouse WS. Restoration of insulin-like growth factor I action in skeletal muscle of old mice. Am J Physiol. 1998;275:E525-E530.
108. Cao JJ, Kurimoto P, Boudignon B, Rosen C, Lima F, Halloran BP. Aging impairs IGF-I receptor activation and induces skeletal resistance to IGF-I. J Bone Miner Res. 2007;22:1271-1279. (Pubitemid 351339709)
109. Wang M, Zhang J, Jiang LQ, et al. Proinflammatory profile within the grossly normal aged human aortic wall. Hypertension. 2007;50:219-227. (Pubitemid 46986044)
110. Rieu I, Magne H, Savary-Auzeloux I, et al. Reduction of low grade inflammation restores blunting of postprandial muscle anabolism and limits sarcopenia in old rats. J Physiol. 2009;587:5483-5492.
111. Degens H. The role of systemic inflammation in age-related muscle weakness and wasting. Scand J Med Sci Sports. 2010;20:28-38.
112. Hammers DW, Matheny RW Jr, Sell C, et al. Impairment of IGF-I expression and anabolic signaling following ischemia/reperfusion in skeletal muscle of old mice. Exp Gerontol. 2011;46:265-272.
113. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999;340:115-126.
114. Matata BM, Galinanes M. Peroxynitrite is an essential component of cytokines production mechanism in human monocytes through modulation of nuclear factor-kappa B DNA binding activity. J Biol Chem. 2002;277:2330-2335. (Pubitemid 34968820)
115. Succurro E, Andreozzi F, Sciaqua A, Hribal ML, Perticone F, Sesti G. Reciprocal association of plasma IGF-1 and interleukin-6 levels with cardiometabolic risk factors in nondiabetic subjects. Diabetes Care. 2008;31:1886-1888.
116. Jeschke MG, Barrow RE, Herndon DN. Insulinlike growth factor I plus insulinlike growth factor binding protein 3 attenuates the proinflammatory acute phase response in severely burned children. Ann Surg. 2000;231:246-252. (Pubitemid 30078808)
117. Spies M, Wolf SE, Barrow RE, Jeschke MG, Herndon DN. Modulation of types I and II acute phase reactants with insulin-like growth factor-1/binding protein-3 complex in severely burned children. Crit Care Med. 2002;30:83-88. (Pubitemid 34112181)
118. Cappola AR, Xue QL, Ferrucci L, Guralnik JM, Volpato S, Fried LP. Insulin-like growth factor I and interleukin-6 contribute synergistically to disability and mortality in older women. J Clin Endocrinol Metab. 2003;88:2019-2025. (Pubitemid 36549871)
119. Serri O, Li L, Maingrette F, Jaffry N, Renier G. Enhanced lipoprotein lipase secretion and foam cell formation by macrophages of patients with growth hormone deficiency: possible contribution to increased risk of atherogenesis? J Clin Endocrinol Metab. 2004;89:979-985. (Pubitemid 38269921)
120. Hochberg Z, Hertz P, Maor G, Oiknine J, Aviram M. Growth hormone and insulin-like growth factor-I increase macrophage uptake and degradation of low density lipoprotein. Endocrinology. 1992;131:430-435.
121. Kirstein M, Aston C, Hintz R, Vlassara H. Receptor-specific induction of insulin-like growth factor I in human monocytes by advanced glycosylation end product-modified proteins. J Clin Invest. 1992;90:439-446.
122. Fournier T, Riches DW, Winston BW, et al. Divergence in macrophage insulin-like growth factor-I (IGF-I) synthesis induced by TNF-alpha and prostaglandin E2. J Immunol. 1995;155:2123-2133.
123. Delafontaine P, Ku L. Reactive oxygen species stimulate insulin-like growth factor I synthesis in vascular smooth muscle cells. Cardiovasc Res. 1997;33:216-222. (Pubitemid 27019118)
124. Du J, Peng T, Scheidegger KJ, Delafontaine P. Angiotensin II activation of insulin-like growth factor 1 receptor transcription is mediated by a tyrosine kinase-dependent redox-sensitive mechanism. Arterioscler Thromb Vasc Biol. 1999;19:2119-2126. (Pubitemid 29422243)
125. Tabet F, Schiffrin EL, Touyz RM. Mitogen-activated protein kinase activation by hydrogen peroxide is mediated through tyrosine kinase-dependent, protein kinase C-independent pathways in vascular smooth muscle cells: upregulation in spontaneously hypertensive rats. J Hypertens. 2005;23:2005-2012. (Pubitemid 41830395)
126. Azar ZM, Mehdi MZ, Srivastava AK. Activation of insulin-like growth factor type-1 receptor is required for H2O2-induced PKB phosphorylation in vascular smooth muscle cells. Can J Physiol Pharmacol. 2006;84:777-786. (Pubitemid 44897898)
127. Gorlach A, Brandes RP, Bassus S, et al. Oxidative stress and expression of p22phox are involved in the up-regulation of tissue factor in vascular smooth muscle cells in response to activated platelets. FASEB J. 2000;14:1518-1528. (Pubitemid 30636556)
128. Loh K, Deng H, Fukushima A, et al. Reactive oxygen species enhance insulin sensitivity. Cell Metab. 2009;10:260-272.
129. Wu DC, Re DB, Nagai M, Ischiropoulos H, Przedborski S. The inflammatory NADPH oxidase enzyme modulates motor neuron degeneration in amyotrophic lateral sclerosis mice. Proc Natl Acad Sci USA. 2006;103:12132-12137. (Pubitemid 44215823)
130. Gardner CD, Eguchi S, Reynolds CM, Eguchi K, Frank GD, Motley ED. Hydrogen peroxide inhibits insulin signaling in vascular smooth muscle cells. Exp Biol Med (Maywood). 2003;228:836-842. (Pubitemid 37169269)
131. Zhong J, Lee WH. Hydrogen peroxide attenuates insulin-like growth factor-1 neuroprotective effect, prevented by minocycline. Neurochem Int. 2007;51:398-404. (Pubitemid 47503461)
132. Simon HU, Haj-Yehia A, Levi-Schaffer F. Role of reactive oxygen species (ROS) in apoptosis induction. Apoptosis. 2000;5:415-418. (Pubitemid 32162623)
133. Clarke MC, Figg N, Maguire JJ, et al. Apoptosis of vascular smooth muscle cells induces features of plaque vulnerability in atherosclerosis. Nat Med. 2006;12:1075-1080. (Pubitemid 44353389)
134. Clarke MC, Littlewood TD, Figg N, et al. Chronic apoptosis of vascular smooth muscle cells accelerates atherosclerosis and promotes calcification and medial degeneration. Circ Res. 2008;102:1529-1538.
135. Okura Y, Brink M, Itabe H, Scheidegger KJ, Kalangos A, Delafontaine P. Oxidized low-density lipoprotein is associated with apoptosis of vascular smooth muscle cells in human atherosclerotic plaques. Circulation. 2000;102:2680-2686.
136. Okura Y, Brink M, Zahid AA, Anwar A, Delafontaine P. Decreased expression of insulin-like growth factor-1 and apoptosis of vascular smooth muscle cells in human atherosclerotic plaque. J Mol Cell Cardiol. 2001;33:1777-1789. (Pubitemid 32977132)
137. Patel VA, Zhang QJ, Siddle K, et al. Defect in insulin-like growth factor-1 survival mechanism in atherosclerotic plaque-derived vascular smooth muscle cells is mediated by reduced surface binding and signaling. Circ Res. 2001;88:895-902. (Pubitemid 32441467)
138. Wang J, Razuvaev A, Folkersen L, et al. The expression of IGFs and IGF binding proteins in human carotid atherosclerosis, and the possible role of IGF binding protein-1 in the regulation of smooth muscle cell proliferation. Atherosclerosis. 2012;220:102-109.
139. Higashi Y, Peng T, Du J, et al. A redox-sensitive pathway mediates oxidized LDL-induced downregulation of insulin-like growth factor-1 receptor. J Lipid Res. 2005;46:1266-1277. (Pubitemid 43109841)
140. Chakrabarti SK, Cole BK, Wen Y, Keller SR, Nadler JL. 12/15-lipoxygenase
141. Seiler A, Schneider M, Forster H, et al. Glutathione peroxidase 4 senses and translates oxidative stress into 12/15-lipoxygenase dependent-and AIF-mediated cell death. Cell Metab. 2008;8:237-248.
142. Li Y, Higashi Y, Itabe H, Song YH, Du J, Delafontaine P. Insulin-like growth factor-1 receptor activation inhibits oxidized LDL-induced cytochrome C release and apoptosis via the phosphatidylinositol 3 kinase/Akt signaling pathway. Arterioscler Thromb Vasc Biol. 2003;23:2178-2184. (Pubitemid 37532317)
143. Jia G, Cheng G, Gangahar DM, Agrawal DK. Insulin-like growth factor-1 and TNF-alpha regulate autophagy through c-jun N-terminal kinase and Akt pathways in human atherosclerotic vascular smooth cells. Immunol Cell Biol. 2006;84:448-454. (Pubitemid 44286038)
144. Hayashi K, Saga H, Chimori Y, Kimura K, Yamanaka Y, Sobue K. Differentiated phenotype of smooth muscle cells depends on signaling pathways through insulin-like growth factors and phosphatidylinositol 3-kinase. J Biol Chem. 1998;273:28860-28867. (Pubitemid 28507577)
145. Ruiz-Torres A, Melon J, Munoz FJ. Insulin stimulates collagen synthesis in vascular smooth muscle cells from elderly patients. Gerontology. 1998;44:144-148. (Pubitemid 28185334)
146. Verma S, Anderson TJ. Fundamentals of endothelial function for the clinical cardiologist. Circulation. 2002;105:546-549. (Pubitemid 34123425)
147. Celermajer DS, Sorensen KE, Spiegelhalter DJ, Georgakopoulos D, Robinson J, Deanfield JE. Aging is associated with endothelial dysfunction in healthy men years before the age-related decline in women. J Am Coll Cardiol. 1994;24:471-476. (Pubitemid 24246550)
148. Hamilton CA, Brosnan MJ, McIntyre M, Graham D, Dominiczak AF. Superoxide excess in hypertension and aging: a common cause of endothelial dysfunction. Hypertension. 2001;37:529-534. (Pubitemid 32199023)
149. Kung CF, Luscher TF. Different mechanisms of endothelial dysfunction with aging and hypertension in rat aorta. Hypertension. 1995;25:194-200.
150. Csiszar A, Wang M, Lakatta EG, Ungvari Z. Inflammation and endothelial dysfunction during aging: role of NF-kappaB. J Appl Physiol. 2008;105:1333-1341.
151. Zheng JS, Yang XQ, Lookingland KJ, et al. Gene transfer of human guanosine 5′-triphosphate cyclohydrolase I restores vascular tetrahydrobiopterin level and endothelial function in low renin hypertension. Circulation. 2003;108:1238-1245. (Pubitemid 37099994)
152. Elhadd TA, Abdu TA, Oxtoby J, et al. Biochemical and biophysical markers of endothelial dysfunction in adults with hypopituitarism and severe GH deficiency. J Clin Endocrinol Metab. 2001;86:4223-4232. (Pubitemid 32848539)
153. Colao A, di Somma C, Pivonello R, et al. The cardiovascular risk of adult GH deficiency (GHD) improved after GH replacement and worsened in untreated GHD: a 12-month prospective study. J Clin Endocrinol Metab. 2002;87:1088-1093. (Pubitemid 36121071)
154. Perticone F, Sciacqua A, Perticone M, et al. Low-plasma insulin-like growth factor-I levels are associated with impaired endothelium-dependent vasodilatation in a cohort of untreated, hypertensive Caucasian subjects. J Clin Endocrinol Metab. 2008;93:2806-2810. (Pubitemid 352008555)
155. Fryburg DA. NG-monomethyl-L-arginine inhibits the blood flow but not the insulin-like response of forearm muscle to IGF-I: possible role of nitric oxide in muscle protein synthesis. J Clin Invest. 1996;97:1319-1328.
156. Pendergrass M, Fazioni E, Collins D, DeFronzo RA. IGF-I increases forearm blood flow without increasing forearm glucose uptake. Am J Physiol. 1998;275:E345-E350.
157. Imrie H, Abbas A, Viswambharan H, et al. Vascular insulin-like growth factor-I resistance and diet-induced obesity. Endocrinology. 2009;150:4575-4582.
158. Holly JM, Amiel SA, Sandhu RR, Rees LH, Wass JA. The role of growth hormone in diabetes mellitus. J Endocrinol. 1988;118:353-364.
159. Michell BJ, Griffiths JE, Mitchelhill KI, et al. The Akt kinase signals directly to endothelial nitric oxide synthase. Curr Biol. 1999;9:845-848. (Pubitemid 29375190)
160. Elzaouk L, Leimbacher W, Turri M, et al. Dwarfism and low insulin-like growth factor-1 due to dopamine depletion in Pts-/-mice rescued by feeding neurotransmitter precursors and H4-biopterin. J Biol Chem. 2003;278:28303-28311. (Pubitemid 36900032)
161. Tanaka J, Koshimura K, Murakami Y, Kato Y. Possible involvement of tetrahydrobiopterin in the trophic effect of insulin-like growth factor-1 on rat pheochromocytoma-12 (PC12) cells. Neurosci Lett. 2002;328:201-203. (Pubitemid 34804743)
162. Csiszar A, Labinskyy N, Perez V, et al. Endothelial function and vascular oxidative stress in long-lived GH/IGF-deficient Ames dwarf mice. Am J Physiol Heart Circ Physiol. 2008;295:H1882-H1894.
163. Ungvari Z, Gautam T, Koncz P, et al. Vasoprotective effects of life span-extending peripubertal GH replacement in Lewis dwarf rats. J Gerontol A Biol Sci Med Sci. 2010;65:1145-1156.
164. Bailey-Downs LC, Sosnowska D, Toth P, et al. Growth hormone and IGF-1 deficiency exacerbate high-fat diet-induced endothelial impairment in obese Lewis dwarf rats: implications for vascular aging. J Gerontol A Biol Sci Med Sci. 2011. doi:10.1093/gerona/glr197.
165. Bailey-Downs LC, Mitschelen M, Sosnowska D, et al. Liver-specific knockdown of IGF-1 decreases vascular oxidative stress resistance by impairing the Nrf2-dependent antioxidant response: a novel model of vascular aging. J Gerontol A Biol Sci Med Sci. 2012;67A:313-329.
166. Sonntag WE, Carter CS, Ikeno Y, et al. Adult-onset growth hormone and insulin-like growth factor I deficiency reduces neoplastic disease, modifies age-related pathology, and increases life span. Endocrinology. 2005;146:2920-2932. (Pubitemid 41002799)
167. Abbas A, Imrie H, Viswambharan H, et al. The insulin-like growth factor-1 receptor is a negative regulator of nitric oxide bioavailability and insulin sensitivity in the endothelium. Diabetes. 2011;60:2169-2178.
168. Lakatta EG. Cardiovascular regulatory mechanisms in advanced age. Physiol Rev. 1993;73:413-467.
169. Kotsis V, Stabouli S, Karafillis I, Nilsson P. Early vascular aging and the role of central blood pressure. J Hypertens. 2011;29:1847-1853.
170. Sandu OA, Ito M, Begum N. Selected contribution: insulin utilizes NO/cGMP pathway to activate myosin phosphatase via Rho inhibition in vascular smooth muscle. J Appl Physiol. 2001;91:1475-1482. (Pubitemid 32803948)
171. Standley PR, Zhang F, Ram JL, Zemel MB, Sowers JR. Insulin attenuates vasopressin-induced calcium transients and a voltage-dependent calcium response in rat vascular smooth muscle cells. J Clin Invest. 1991;88:1230-1236.
172. Galderisi M, Vitale G, Lupoli G, et al. Inverse association between free insulin-like growth factor-1 and isovolumic relaxation in arterial systemic hypertension. Hypertension. 2001;38:840-845. (Pubitemid 34258680)
173. Colao A, Di Somma C, Cascella T, et al. Relationships between serum IGF1 levels, blood pressure, and glucose tolerance: an observational, exploratory study in 404 subjects. Eur J Endocrinol. 2008;159:389-397.
174. Tivesten A, Bollano E, Andersson I, et al. Liver-derived insulin-like growth factor-I is involved in the regulation of blood pressure in mice. Endocrinology. 2002;143:4235-4242. (Pubitemid 35239553)
175. Vecchione C, Colella S, Fratta L, et al. Impaired insulin-like growth factor I vasorelaxant effects in hypertension. Hypertension. 2001;37:1480-1485. (Pubitemid 34225395)
176. Hongo K, Nakagomi T, Kassell NF, et al. Effects of aging and hypertension on endothelium-dependent vascular relaxation in rat carotid artery. Stroke. 1988;19:892-897.
177. Hasdai D, Holmes DR Jr, Richardson DM, Izhar U, Lerman A. Insulin and IGF-I attenuate the coronary vasoconstrictor effects of endothelin-1 but not of sarafotoxin 6c. Cardiovasc Res. 1998;39:644-650. (Pubitemid 28407597)
178. Duerrschmidt N, Wippich N, Goettsch W, Broemme HJ, Morawietz H. Endothelin-1 induces NAD(P)H oxidase in human endothelial cells. Biochem Biophys Res Commun. 2000;269:713-717. (Pubitemid 30440367)
179. Li L, Fink GD, Watts SW, et al. Endothelin-1 increases vascular superoxide via endothelin(A)-NADPH oxidase pathway in low-renin hypertension. Circulation. 2003;107:1053-1058. (Pubitemid 36258731)
180. Wedgwood S, McMullan DM, Bekker JM, Fineman JR, Black SM. Role for endothelin-1-induced superoxide and peroxynitrite production in rebound pulmonary hypertension associated with inhaled nitric oxide therapy. Circ Res. 2001;89:357-364. (Pubitemid 34132675)
181. Frank HJ, Levin ER, Hu RM, Pedram A. Insulin stimulates endothelin binding and action on cultured vascular smooth muscle cells. Endocrinology. 1993;133:1092-1097. (Pubitemid 23267759)
182. Kwok CF, Juan CC, Shih KC, Hwu CM, Jap TS, Ho LT. Insulin-like growth factor-1 increases endothelin receptor A levels and action in cultured rat aortic smooth muscle cells. J Cell Biochem. 2005;94:1126-1134. (Pubitemid 41420235)
183. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997;275:964-967. (Pubitemid 27087709)
184. Werner N, Kosiol S, Schiegl T, et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med. 2005;353:999-1007. (Pubitemid 41262334)
185. Alev C, Ii M, Asahara T. Endothelial progenitor cells: a novel tool for the therapy of ischemic diseases. Antioxid Redox Signal. 2011;15:949-965.
186. Foteinos G, Hu Y, Xiao Q, Metzler B, Xu Q. Rapid endothelial turnover in atherosclerosis-prone areas coincides with stem cell repair in apolipoprotein E-deficient mice. Circulation. 2008;117:1856-1863. (Pubitemid 351507474)
187. Walter DH, Rittig K, Bahlmann FH, et al. Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation. 2002;105:3017-3024. (Pubitemid 34693836)
188. Aicher A, Heeschen C, Mildner-Rihm C, et al. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat Med. 2003;9:1370-1376. (Pubitemid 37466185)
189. Thum T, Fraccarollo D, Schultheiss M, et al. Endothelial nitric oxide synthase uncoupling impairs endothelial progenitor cell mobilization and function in diabetes. Diabetes. 2007;56:666-674. (Pubitemid 46348461)
190. Dernbach E, Urbich C, Brandes RP, Hofmann WK, Zeiher AM, Dimmeler S. Antioxidative stress-associated genes in circulating progenitor cells: evidence for enhanced resistance against oxidative stress. Blood. 2004;104:3591-3597. (Pubitemid 39564432)
191. He T, Peterson TE, Holmuhamedov EL, et al. Human endothelial progenitor cells tolerate oxidative stress due to intrinsically high expression of manganese superoxide dismutase. Arterioscler Thromb Vasc Biol. 2004;24:2021-2027. (Pubitemid 39482424)
192. Haddad P, Dussault S, Groleau J, et al. Nox2-containing NADPH oxidase deficiency confers protection from hindlimb ischemia in conditions of increased oxidative stress. Arterioscler Thromb Vasc Biol. 2009;29:1522-1528.
193. Ingram DA, Krier TR, Mead LE, et al. Clonogenic endothelial progenitor cells are sensitive to oxidative stress. Stem Cells. 2007;25:297-304. (Pubitemid 46232783)
194. Urao N, Inomata H, Razvi M, et al. Role of nox2-based NADPH oxidase in bone marrow and progenitor cell function involved in neovascularization induced by hindlimb ischemia. Circ Res. 2008;103:212-220.
195. Rauscher FM, Goldschmidt-Clermont PJ, Davis BH, et al. Aging, progenitor cell exhaustion, and atherosclerosis. Circulation. 2003;108:457-463. (Pubitemid 36935540)
196. Thum T, Fleissner F, Klink I, et al. Growth hormone treatment improves markers of systemic nitric oxide bioavailability via insulin-like growth factor-I. J Clin Endocrinol Metab. 2007;92:4172-4179. (Pubitemid 350074728)
197. Thum T, Hoeber S, Froese S, et al. Age-dependent impairment of endothelial progenitor cells is corrected by growth-hormone-mediated increase of insulin-like growth-factor-1. Circ Res. 2007;100:434-443.
198. Yoder MC. Defining human endothelial progenitor cells. J Thromb Haemost. 2009;7(suppl 1):49-52.
199. Tilki D, Hohn HP, Ergun B, Rafii S, Ergun S. Emerging biology of vascular wall progenitor cells in health and disease. Trends Mol Med. 2009;15:501-509.